Shattuck Labs Q4 net loss narrows on lower R&D spend

Overview

• Biotechnology firm reported Q4 net loss of $12.6 mln, improved from prior year

• Company's Q4 R&D expenses fell to $9.1 mln from $15.4 mln yr/yr

• Raised $21.4 mln in Q1 2026 via share sales, boosting cash reserves

Outlook

• Shattuck expects to release Phase 1 data for SL-325 in Q2 2026

• Shattuck's cash expected to fund operations into 2029

Result Drivers

• R&D EXPENSES REDUCTION - Decrease in R&D expenses due to discontinuation of SL-172154 program, allowing focus on SL-325

Company press release: ID:nGNX1D9pQ5

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Shattuck Labs Inc is $5.00, about 5.7% above its March 4 closing price of $4.73

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.